Child's Nervous System

, Volume 19, Issue 9, pp 655–658 | Cite as

Serum α1-antitrypsin level and phenotype associated with familial moyamoya disease

  • Toshiyuki Amano
  • Satoshi Inoha
  • Chun-Ming Wu
  • Toshio Matsushima
  • Kiyonobu Ikezaki
Original Paper



Obstructive vascular lesions at the terminal portion of the internal carotid arteries are thought to be the primary and essential lesions in moyamoya disease. The etiology remains unknown. To detect possible mediators of the thickened intima of moyamoya disease, we measured serum alpha-1-antitrypsin (α1-AT) levels and characterized the phenotype of patients with familial moyamoya disease.

Patients and methods

Fifty-six individuals were examined, including 29 patients with moyamoya disease from 14 families. Serum α1-AT levels were analyzed by electroimmunoassay and genomic phenotype by isoelectric focusing.


All individuals had a normal α1-AT phenotype. The average serum α1-AT level in moyamoya disease patients was significantly higher than that of normal individuals, although both were within the normal range.


These findings suggest that serum α1-AT level may be a marker, rather than an etiologic factor, indicating the progression of moyamoya disease.


Moyamoya disease Alpha-1-antitrypsin 



This work was supported by Grants from the Research on Cardiovascular Disease (12C-4), and the Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya disease) of the Ministry of Health, Labor and Welfare of Japan.


  1. 1.
    Aoyagi M, Fukai N, Sakamoto H, Shinkai T, Matsushima Y, Yamamoto M, Yamamoto K (1991) Altered cellular responses to serum mitogens, including platelet-derived growth factor, in cultured smooth muscle cells derived from arteries of patients with moyamoya disease. J Cell Physiol 147:191–198PubMedGoogle Scholar
  2. 2.
    Aoyagi M, Ogami K, Matsushima Y, Shikata M, Yamamoto M, Yamamoto K (1995) Human leukocyte antigen in patients with moyamoya disease. Stroke 26:415–417PubMedGoogle Scholar
  3. 3.
    Aoyagi M, Fukai N, Yamamoto M, Nakagawa K, Matsushima Y, Yamamoto K (1996) Early development of intimal thickening in superficial temporal arteries in patients with moyamoya disease. Stroke 27:1750–1754PubMedGoogle Scholar
  4. 4.
    Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC, Vaughan L, Boswell DR (1982) Structure and variation of human α1-antitrypsin. Nature 298:329–334PubMedGoogle Scholar
  5. 5.
    Cox DW (1994) α1-Antitrypsin: a guardian of vascular tissue. Mayo Clin Proc 69:1123–1124PubMedGoogle Scholar
  6. 6.
    Duranton J, Adam C, Bieth JG (1998) Kinetic mechanism of the inhibition of catepsin G by α1-antichymotrypsin and α1-proteinase inhibitor. Biochemistry 37:11239–11245CrossRefPubMedGoogle Scholar
  7. 7.
    Eriksson S (1996) A 30-year perspective on α1-antitrypsin deficiency. Chest 110 [Suppl]:S237–S242Google Scholar
  8. 8.
    Faber JP, Poller W, Weidinger S, Kirchgesser M, Schwaab R, Bidlingmaier F, Olek K (1994) Identification and DNA sequence analysis of 15 new α1-antitrypsin variants, including two PIQ0 alleles and one deficient PIM allele. Am J Hum Genet 55:1113–1121PubMedGoogle Scholar
  9. 9.
    Fukui M (1997) Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ("moyamoya disease"). Research Committee on Spontaneous Occlusion of the Circle of Willis (moyamoya disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg 99 [Suppl 2]:S238–S240Google Scholar
  10. 10.
    Fukuyama Y, Osawa M, Kanai N (1992) Moyamoya disease (syndrome) and the Down syndrome. Brain Dev 14:254–256PubMedGoogle Scholar
  11. 11.
    Ikari Y, Mulvihill E, Schwartz SM (2001) 1-Proteinase inhibitor, α1-antichymotrypsin, and, α2-macrogloblin are the antiapoptotic factors of vascular smooth muscle cells. J Biol Chem 276:11798–11830CrossRefPubMedGoogle Scholar
  12. 12.
    Ikeda E (1991) Systemic vascular changes in spontaneous occlusion of the circle of Willis. Stroke 22:1358–1362PubMedGoogle Scholar
  13. 13.
    Ikeda E, Hosoda Y (1992) Spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease): with special reference to its clinicopathological identity. Brain Dev 14:251–253PubMedGoogle Scholar
  14. 14.
    Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T (1999) Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 64:533–537CrossRefPubMedGoogle Scholar
  15. 15.
    Ikezaki K, Han DH, Kawano T, Kinukawa N, Fukui M (1997) A clinical comparison of definite moyamoya disease between South Korea and Japan. Stroke 28:2513–2517PubMedGoogle Scholar
  16. 16.
    Ikezaki K, Kono S, Fukui M (2001) Etiology of moyamoya disease: pathology, pathophysiology, and genetics. In: Ikezaki K (ed) Moyamoya disease. American Association of Neurological Surgeons, Rolling Meadows, pp 55–64Google Scholar
  17. 17.
    Inoue TK, Ikezaki K, Sasazuki T, Ono T, Kamikawaji N, Matsushima T, Fukui M (1997) DNA typing of HLA in the patients with moyamoya disease. Jpn J Hum Genet 42:507–515PubMedGoogle Scholar
  18. 18.
    Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M (2000) Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 15:179–182PubMedGoogle Scholar
  19. 19.
    Kalsheker NA (1996) α1-antichymotrypsin. Int J Biochem Cell Biol 28:961–964CrossRefPubMedGoogle Scholar
  20. 20.
    Kueppers F (1976) Determination of α1-antitrypsin phenotypes by isoelectric focusing in polyacrylamide gels. J Lab Clin Med 88:151–155PubMedGoogle Scholar
  21. 21.
    Luft FC (1999) Alpha-1-antitrypsin and its relevance to human disease. J Mol Med 77:359–360CrossRefPubMedGoogle Scholar
  22. 22.
    Luscher TF, Stanson AW, Houser OW, Hollier LH, Sheps SG (1986) Arterial fibromuscular dysplasia. Mayo Clin Proc 62:931–952Google Scholar
  23. 23.
    Masuda J, Ogata J, Yutani C (1993) Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke 24:1960–1967PubMedGoogle Scholar
  24. 24.
    Schievink WI, Prakash UBS, Piepgras DG, Mokri B (1994) α1-Antitrypsin deficiency in intracranial aneurysms and cervical artery dissection. Lancet 343:452–453PubMedGoogle Scholar
  25. 25.
    Schievink WI, Katzmann JA, Piepgras DG, Schaid DJ (1996) Alpha-1-antitrypsin phenotypes among patients with intracranial aneurysms. J Neurosurg 84:781–784PubMedGoogle Scholar
  26. 26.
    Schievink WI, Meyer FB, Parisi JE, Wijdicks EFM (1998) Fibromuscular dysplasia of the internal carotid artery associated with α1-antitrypsin deficiency. Neurosurgery 43:229–234Google Scholar
  27. 27.
    Soriano SG, Cowan DB, Proctor MR, Scott RM (2002) Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya disease. Neurosurgery 50:544–549PubMedGoogle Scholar
  28. 28.
    St Jean P, Hart B, Webster M, Steed D, Adamson J, Powell J, Ferrell R (1996) Alpha-1-antitrypsin deficiency in aneurysmal disease. Hum Hered 46:92–97PubMedGoogle Scholar
  29. 29.
    Yamamoto M, Aoyagi M, Tajima S, Wachi H, Fukai N, Matsushima Y, Yamamoto K (1997) Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke 28:1733–1738PubMedGoogle Scholar
  30. 30.
    Yamamoto M, Aoyagi M, Fukai N, Matsushima Y, Yamamoto K (1998) Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke 29:1188–1193PubMedGoogle Scholar
  31. 31.
    Yamamoto M, Aoyagi M, Fukai N, Matsushima Y, Yamamoto K (1999) Increase in prostaglandin E2 production by interleukin-1β in arterial smooth muscle cells derived from patients with moyamoya disease. Circ Res 85:912–918PubMedGoogle Scholar
  32. 32.
    Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, Abe H, Inoue TK, Ikezaki K, Matsushima T, Fukui M (2000) Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31:930–935PubMedGoogle Scholar
  33. 33.
    Yonekawa Y, Ogata N (1992) Spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease): with special reference to its disease entity and etiological controversy. Brain Dev 14:253–254PubMedGoogle Scholar
  34. 34.
    Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG (1997) Moyamoya disease in Europe: past and present status. Clin Neurol Neurosurg 99 [Suppl 2]:S58–S60Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Toshiyuki Amano
    • 1
  • Satoshi Inoha
    • 1
  • Chun-Ming Wu
    • 1
  • Toshio Matsushima
    • 1
  • Kiyonobu Ikezaki
    • 1
  1. 1.Department of Neurosurgery, Graduate School of Medical SciencesKyushu UniversityHigashi-ku, FukuokaJapan

Personalised recommendations